AU2013352294A1 - Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid - Google Patents

Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid Download PDF

Info

Publication number
AU2013352294A1
AU2013352294A1 AU2013352294A AU2013352294A AU2013352294A1 AU 2013352294 A1 AU2013352294 A1 AU 2013352294A1 AU 2013352294 A AU2013352294 A AU 2013352294A AU 2013352294 A AU2013352294 A AU 2013352294A AU 2013352294 A1 AU2013352294 A1 AU 2013352294A1
Authority
AU
Australia
Prior art keywords
mepe
mice
syndrome
treatment
autism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013352294A
Other languages
English (en)
Inventor
Michael John Bickerdike
Patricia Perez DE COGRAM
Lawrence Irwin Glass
Michael Frederick Snape
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of AU2013352294A1 publication Critical patent/AU2013352294A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2013352294A 2012-11-28 2013-11-26 Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid Abandoned AU2013352294A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730829P 2012-11-28 2012-11-28
US61/730,829 2012-11-28
PCT/US2013/072049 WO2014085480A1 (fr) 2012-11-28 2013-11-26 Traitement de troubles du spectre autistique à l'aide de l'acide glycyl-l-2-méthylprolyl-l-glutamique

Publications (1)

Publication Number Publication Date
AU2013352294A1 true AU2013352294A1 (en) 2015-07-09

Family

ID=50828422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013352294A Abandoned AU2013352294A1 (en) 2012-11-28 2013-11-26 Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid

Country Status (6)

Country Link
EP (1) EP2928300A4 (fr)
JP (1) JP2016506380A (fr)
AU (1) AU2013352294A1 (fr)
BR (1) BR112015012506A2 (fr)
CA (1) CA2929286A1 (fr)
WO (1) WO2014085480A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10254785B2 (en) 2014-06-30 2019-04-09 Cerora, Inc. System and methods for the synchronization of a non-real time operating system PC to a remote real-time data collecting microcontroller
BR112021002456A2 (pt) * 2018-08-10 2021-05-04 New York University método de tratamento de um distúrbio do neurodesenvolvimento, composto, e, composição

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401808B1 (fr) * 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Peptidomimetiques et analogues de gpe
US8637567B2 (en) * 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
WO2006127702A2 (fr) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogues de glycyl-prolyl-glutamate
US8461148B2 (en) * 2004-09-20 2013-06-11 Icahn School Of Medicine At Mount Sinai Use of memantine (namenda) to treat autism, compulsivity and impulsivity
WO2007106555A2 (fr) * 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Préparations orales de glycyl-2-méthylpropyl-glutamate
JP2010510314A (ja) * 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
EP2571515B1 (fr) * 2010-05-17 2016-11-30 Icahn School of Medicine at Mount Sinai Procédés et tests pour le traitement de sujets présentant une délétion, une mutation ou une expression réduite de shank3
EP2667715B1 (fr) * 2011-01-27 2017-07-19 Neuren Pharmaceuticals Limited Traitement de troubles du spectre autistique en utilisant l'acide glycyl-l-2-méthylprolyl-l-glutamique

Also Published As

Publication number Publication date
EP2928300A1 (fr) 2015-10-14
WO2014085480A1 (fr) 2014-06-05
CA2929286A1 (fr) 2014-06-05
JP2016506380A (ja) 2016-03-03
BR112015012506A2 (pt) 2017-07-11
EP2928300A4 (fr) 2016-07-13

Similar Documents

Publication Publication Date Title
JP6640275B2 (ja) グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
US20150224164A1 (en) Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
US11197856B2 (en) Bicyclic compounds and methods for their use in treating autism
US20210169964A1 (en) Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
AU2013352294A1 (en) Treatment of Autism Spectrum Disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US20190091284A1 (en) Amidated Dopamine Neuron Stimulating Peptides for CNS Dopaminergic Upregulation
US20180117113A1 (en) Amidated Dopamine Neuron Stimulating Peptide Restoration of Mitochondrial Activity
Schaan Profes The role of autophagy in the growth and guidance of midbrain dopaminergic neurons

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period